4//SEC Filing
Gemphire Therapeutics Inc. 4
Accession 0001104659-16-139254
$MTVACIK 0001638287operating
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 12:47 PM ET
Size
19.3 KB
Accession
0001104659-16-139254
Insider Transaction Report
Form 4
Bisgaier Charles PhD
DirectorChair & Chief Scientific Off.10% Owner
Transactions
- Conversion
Common Stock
2016-08-10+59,561→ 59,561 total(indirect: By Trust) - Conversion
Common Stock
2016-08-10$6.71/sh+16,144$108,260→ 82,220 total(indirect: By Trust) - Conversion
Common Stock
2016-08-10$6.71/sh+19,228$128,941→ 19,228 total(indirect: By LLC) - Purchase
Common Stock
2016-08-10$10.00/sh+51,750$517,500→ 1,244,440 total - Conversion
Series A Convertible Preferred Stock
2016-08-10−59,561→ 0 total(indirect: By Trust)→ Common Stock (59,561 underlying) - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By Trust)Exercise: $6.71→ Common Stock (16,144 underlying) - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By LLC)Exercise: $6.71→ Common Stock (19,228 underlying) - Other
Common Stock
2016-08-10$6.71/sh+6,515$43,689→ 66,076 total(indirect: By Trust)
Footnotes (5)
- [F1]The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
- [F2]These shares are indirectly owned by the reporting person as trustee of The Charles L. Bisgaier Trust.
- [F3]Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
- [F4]The notes were issued in the original principal amount of $100,000. The outstanding principal and $8,263 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.
- [F5]The notes were issued in the original principal amount of $125,000. The outstanding principal and $3,945 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.
Documents
Issuer
Gemphire Therapeutics Inc.
CIK 0001638287
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001638287
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 12:47 PM ET
- Size
- 19.3 KB